As for HER-2-positive tumors, accounting for 10–30% of gastric cancer cases [7], one of the main concerns is the heterogeneity of this biomarker within the tumor, which may restrict patient selection and accrual for clinical trials. The gene discussed is ERBB2; the disease is neoplasm.